Bruton’s tyrosine kinase (BTK) inhibitors (BTKi) have been developed since 1999 and ibrutinib was the first in class drug, initially approved for treating relapsed/refractory Mantle cell Lymphoma (73). Here, BTK is linked to mantle cell lymphoma.